Fast Track Heart Attack Diagnosis: Is the FDA's Approach Safe?
"A new study examines the effectiveness of a rapid diagnostic algorithm for myocardial infarction (MI) using the FDA-approved high-sensitivity troponin T assay."
Diagnosing a myocardial infarction (MI) quickly is critical for saving lives. Recently, the FDA approved a new high-sensitivity cardiac troponin T (hs-cTnT) assay, offering a potentially faster way to detect heart attacks. For years, countries in Europe, Australia, and Canada have been using more sensitive tests which helped them quickly identify MI cases at an early stage.
These countries developed what's called the 0/1-h algorithm. This strategy involves measuring troponin levels at the patient's arrival to the emergency department (ED) and again after just one hour. Based on these levels, doctors can quickly decide whether to rule out or rule in MI.
However, the FDA's approved version of the hs-cTnT assay has a couple of key differences compared to how it's used elsewhere. First, it reports very low concentrations differently. Second, the FDA-approved 99th percentile upper reference limit (19 ng/l) is a bit higher. Given these differences, a new study was needed to see how well the 0/1-h algorithm performs in the FDA-approved setting.
How Heart Attacks Are Diagnosed
Heart attack diagnosis can involve blood tests and cardiac tests. When heart muscle cells die, they release proteins into the bloodstream; a troponin test measures one such protein, and blood tests are often repeated to check for changes over time. The 2018 Fourth Universal Definition of Myocardial Infarction distinguished acute myocardial infarction from myocardial injury and classified MI into five types. Late gadolinium enhancement imaging assesses myocardial necrosis using premises first established in experimental studies of acute myocardial infarction.
From Fatal Disease to Recognizable Diagnosis
A historical review describes acute myocardial infarction as a disease considered fatal in the early 1900s, while characterizing later progress in diagnosis, management, and treatment as a history of success. It presents historical milestones as useful context for understanding modern disease management and continuing clinical dilemmas. In a 1920 report, Harold Pardee described the electrocardiographic changes associated with STEMI, or ST-elevation myocardial infarction, as a sign of coronary artery obstruction.
Does the FDA-Approved Approach Compromise Accuracy?
Researchers conducted a large, multi-center study to evaluate the 0/1-h algorithm using the FDA-approved hs-cTnT assay. The study involved patients presenting to the ED with suspected MI, excluding those with ST-segment elevation MI. Two independent cardiologists reviewed each case to make a final diagnosis, considering all available clinical information.
- Safety First: The negative predictive value (NPV) and sensitivity for MI were extremely high and similar for both the original and modified 0/1-h algorithms (NPV around 99.8-99.9%, sensitivity around 99.4-99.6%).
- Quick Rule-Out: The 0/1-h algorithms effectively ruled out and ruled in MI in approximately 75% of patients.
- Comparable Performance: The rule-in performance was also excellent and comparable between both 0/1-h algorithms.
Troponin Strategies and Emerging Biomarkers
A 2024 article reports that using a high-sensitivity cardiac troponin T (hs-cTnT) measurement of 6 ng/L at 0 hours has been shown to safely rule out acute myocardial infarction. A review of high-sensitivity cardiac troponin in suspected MI notes that the original European Society of Cardiology 0/1-hour algorithm was minimally adapted for the FDA setting. A separate study snippet reports median cMyC of 237 ng/L in adjudicated AMI cases, compared with 62 ng/L for hs-cTnT and 97 ng/L for hs-cTnI; these figures describe the reported study results and do not by themselves establish a preferred diagnostic strategy.
Heart Attack and Myocardial Infarction
The listed sources use “heart attack” as the common name for myocardial infarction. Medscape describes MI as irreversible heart-muscle necrosis following prolonged ischemia, usually due to an imbalance between oxygen supply and demand; it identifies plaque rupture with thrombus formation in a coronary vessel as the most common cause. The available snippets therefore support treating the terms as referring to the same condition, while distinguishing the condition from its underlying mechanism.
The Bottom Line: Rapid, Safe Heart Attack Assessment
The study indicates that the 0/1-h algorithm, when used with the hs-cTnT assay approved by the FDA, offers a safe and effective approach to quickly assess patients with suspected MI. The differences in the FDA-approved assay's reporting and 99th percentile value do not appear to compromise the algorithm's accuracy or safety.
What Expert Review Considers
The listed expert-review sources identify several elements relevant to evaluating a possible missed myocardial infarction: symptoms, ECG interpretation, biomarkers, risk stratification, treatment, and the effect of diagnostic delay. One source describes emergency-medicine expert review of STEMI, NSTEMI, missed diagnosis, and standard of care. These listings describe areas of expertise and review, rather than providing a specific expert conclusion about the safety of an FDA diagnostic approach.
Mortality Trends and Evolving Definitions
A study published in 2026 analyzed U.S. myocardial-infarction- and heart-failure-related mortality trends from 1999 through 2024 and projected rates through 2035; the supplied summaries do not provide the projected figures. The 2026 Fifth Universal Definition snippet describes secondary MI as acute myocardial injury caused by another acute condition that creates an imbalance in myocardial oxygen supply and demand, when accompanied by symptoms or signs of myocardial ischemia. These sources point to continued attention both to population-level mortality and to how MI is defined.
Causes and Timeliness of Care
The World Health Organization describes a heart attack as a sudden interruption of blood flow to part of the heart muscle, most often when a clot forms on a ruptured fatty deposit inside a coronary artery. Another listed source describes secondary myocardial infarction as injury associated with an acute oxygen supply-demand imbalance rather than an acute coronary obstruction, including during severe stress such as septic shock or severe blood loss. A 2020 article says reperfusion therapy should preferably be performed within 12 hours of symptom onset and emphasizes that shorter delays matter.
The Burden Reflected in Case Materials
A Weber State University case-study page reports that approximately one million patients are admitted to U.S. hospitals each year because of heart attacks and that 200,000 to 300,000 people die from heart attacks before receiving medical care. Its snippet also states that heart attack accounts for an estimated one in every five U.S. deaths. These are figures reported by that educational case-study source; the other supplied case-study snippets describe individual patient presentations rather than corroborating those estimates.
For patients, this means potentially faster diagnosis and treatment decisions. For healthcare providers, it provides reassurance that the 0/1-h algorithm can be reliably implemented in the U.S. setting.
Further research may explore ways to optimize the algorithm and improve its performance even further. But for now, the 0/1-h algorithm with the FDA-approved hs-cTnT assay represents a valuable tool for improving the speed and accuracy of heart attack diagnosis.